Evaluation of Self‐Mediated Alternatives for Risk Testing Education and Return of Results ‐ eSMARTER: A randomized trial from the Alzheimer’s Prevention Initiative program
Gespeichert in:
| Veröffentlicht in: | Alzheimer's & Dementia vol. 21 (Dec 1, 2025) |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , , , , , , , , , , , |
| Veröffentlicht: |
John Wiley & Sons, Inc.
|
| Schlagworte: | |
| Online-Zugang: | Citation/Abstract Full Text - PDF |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3286852259 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 1552-5260 | ||
| 022 | |a 1552-5279 | ||
| 024 | 7 | |a 10.1002/alz70859_099986 |2 doi | |
| 035 | |a 3286852259 | ||
| 045 | 0 | |b d20251201 | |
| 100 | 1 | |a Langlois, Carolyn |u Banner Alzheimer's Institute, Phoenix, AZ, USA | |
| 245 | 1 | |a Evaluation of Self‐Mediated Alternatives for Risk Testing Education and Return of Results ‐ eSMARTER: A randomized trial from the Alzheimer’s Prevention Initiative program | |
| 260 | |b John Wiley & Sons, Inc. |c Dec 1, 2025 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a Background Availability of amyloid modifying therapies dramatically increases the need to disclose Alzheimer’s disease (AD) related genetic and/or biomarker test results to inform clinical decision making. An existing shortage of genetic counselors and dementia specialists, coupled with the 21st Century Cures Act requirement to immediately return most medical test results, makes timely development of scalable methods to responsibly communicate test results essential. Method The Evaluation of Self‐Mediated Alternatives for Risk Testing Education and Return of Results (eSMARTER) is a decentralized, randomized, non‐inferiority trial evaluating if disclosure of APOE genotype by participant‐directed scalable digital platforms is non‐inferior to telehealth disclosure with a healthcare provider. Participants also have the option to learn plasma pTau‐217 test results. eSMARTER is enrolling approximately 600 adults aged 60‐80 who have undergone prior APOE testing but report not knowing their APOE results. Participants are randomized to receive results either with via telehealth with a healthcare provider or independently through a digital intervention. Participants in the digital arm can select a web‐based intervention or a chatbot. Participants complete online assessments evaluating cognitive, affective and behavioral patient reported outcomes prior to and at various timepoints after disclosure. Blood samples for pTau‐217 testing and repository storage are collected using remote mobile phlebotomy services. Strategically timed newsletters support participant retention and engagement. Additionally, eSMARTER participants are invited to the ancillary eDROP‐AD study to assess feasibility and acceptance of self‐sampling at‐home using finger prick blood collection with the Capitainer®SEP10 card. Result Enrollment in eSMARTER began in October 2024 and is expected to close in February 2025. Recruitment, screening, and enrollment data will be presented along with participant demographics and key health‐related characteristics. Unique insights and lessons learned from launching a national, decentralized, randomized trial will also be shared. Conclusion The eSMARTER study addresses the need for practical and scalable methods to responsibly communicate AD genetic and/or biomarker results. The eSMARTER digital platforms will be made available to support healthcare providers in returning AD genetic and/or biomarker results to individuals in clinical and research settings. All data and samples collected will be made available for public sharing. | |
| 653 | |a Demography | ||
| 653 | |a Intervention | ||
| 653 | |a Alzheimer's disease | ||
| 653 | |a Telemedicine | ||
| 653 | |a Disclosure | ||
| 653 | |a Decentralization | ||
| 653 | |a Dementia | ||
| 653 | |a Enrollments | ||
| 653 | |a Inferiority | ||
| 653 | |a Blood | ||
| 653 | |a Health care industry | ||
| 653 | |a Self evaluation | ||
| 653 | |a 21st century | ||
| 653 | |a Feasibility | ||
| 653 | |a Specialists | ||
| 653 | |a Recruitment | ||
| 653 | |a Biological markers | ||
| 653 | |a Medical technology | ||
| 653 | |a Alternative approaches | ||
| 653 | |a Prevention programs | ||
| 653 | |a Health services | ||
| 653 | |a Genetic counseling | ||
| 653 | |a Clinical research | ||
| 653 | |a Mental health services | ||
| 653 | |a Telecommunications | ||
| 653 | |a Genetics | ||
| 653 | |a Education | ||
| 653 | |a Newsletters | ||
| 653 | |a Decision making | ||
| 653 | |a Storage | ||
| 653 | |a Health care | ||
| 653 | |a Medical decision making | ||
| 653 | |a Sampling | ||
| 653 | |a Clinical decision making | ||
| 653 | |a Adults | ||
| 653 | |a Medical screening | ||
| 653 | |a Computer platforms | ||
| 653 | |a Blood tests | ||
| 653 | |a Cognitive-behavioral factors | ||
| 653 | |a Biomarkers | ||
| 653 | |a Communication | ||
| 700 | 1 | |a Bradbury, Angela R. |u University of Pennsylvania, Philadelphia, PA, USA | |
| 700 | 1 | |a Wood, Elisabeth |u University of Pennsylvania, Philadelphia, PA, USA | |
| 700 | 1 | |a Harkins, Kristin |u University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA | |
| 700 | 1 | |a Erickson, Claire M |u Banner Alzheimer's Institute, Phoenix, AZ, USA | |
| 700 | 1 | |a Salata, Hayley |u Banner Alzheimer's Institute, Phoenix, AZ, USA | |
| 700 | 1 | |a Walsh, Trisha L |u Banner Alzheimer's Institute, Phoenix, AZ, USA | |
| 700 | 1 | |a Largent, Emily A. |u University of Pennsylvania, Philadelphia, PA, USA | |
| 700 | 1 | |a Egleston, Brian L |u Fox Chase Cancer Center, Philadelphia, PA, USA | |
| 700 | 1 | |a Reiman, Eric M. |u Banner Alzheimer's Institute, Phoenix, AZ, USA | |
| 700 | 1 | |a Grill, Joshua D |u Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA | |
| 700 | 1 | |a Roberts, J. Scott |u University of Michigan School of Public Health, Ann Arbor, MI, USA | |
| 700 | 1 | |a Ashton, Nicholas J. |u Banner Sun Health Research Institute, Sun City, AZ, USA | |
| 700 | 1 | |a Karlawish, Jason |u University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA | |
| 700 | 1 | |a Langbaum, Jessica B. |u Banner Alzheimer's Institute, Phoenix, AZ, USA | |
| 773 | 0 | |t Alzheimer's & Dementia |g vol. 21 (Dec 1, 2025) | |
| 786 | 0 | |d ProQuest |t Consumer Health Database | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3286852259/abstract/embedded/L8HZQI7Z43R0LA5T?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3286852259/fulltextPDF/embedded/L8HZQI7Z43R0LA5T?source=fedsrch |